Phenotyping Sarcoidosis from a Pulmonary Perspective

Abstract

The described SCAC protocol is practicable and gives additional information not yet acquired by radiologic typing and seems suitable for studies evaluating genetic influence and biomarkers.

Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes

“…Consequently, we cannot be certain that, at the time of diagnosis, nonprogressive patients did not exhibit high levels of CXCL9 initially; however, in a subset analysis of all sarcoidosis patients whose baseline visits were within 2 years of diagnosis, the chronic group still exhibited significantly higher CXCL9 expression levels compared with those with nonprogressive disease. Finally, we could not apply the clinical categorisations of acute and nonacute sarcoidosis disease onset reported by PRASSE et al [36], as our cohort consisted of only nonacute disease. As many published studies in sarcoidosis have used a 2-year threshold to define chronic sarcoidosis, we chose this schema as well.…”

Prognostic Factors in Sarcoidosis

“…The same authors reported that only 7 of 31 untreated patients with low sIL2R values, but 8 of 11 with high sIL2R values needed treatment in follow-up observation (meaning that 73 % of patients with high values, but only 23% of patients with low sIL2R had less favorable outcome). Both sIL2R and neopterin were increased in sera of patients who needed treatment in a follow-up, and this effect was especially strongly pronounced in a subgroup of patients with acute symptoms, indicating a rare subpopulation of severe acute sarcoidosis at high risk of progression (Prasse et al, 2008). Another product of inflammatory cells is a mucin-like high molecular weight glycoprotein KL-6.…”

“…For scientific use, patients are frequently divided to "Löfgren" and "nonwww.intechopen.com Löfgren" subgroups, which reflects the obvious differences in prognosis. A novel protocol of phenotyping sarcoidosis was proposed based on these three criteria: 1. the type of onset (acute vs non-acute); 2. the need of treatment; 3. the need of long-term treatment (Prasse et al, 2008). According to these criteria, patients are further classified into 6 classes ( Prasse et al .…”

Assessing the worldwide epidemiology of sarcoidosis: challenges and future directions

“…Ironically, the ACCESS study was not renewed beyond its initial 5-year funding period as no single risk factor emerged as a dominant influence of disease [35]. Given the possibility that the heterogeneous clinical manifestations of sarcoidosis may be evidence of multiple aetiologies [11,12], it may be time to re-visit this type of study design.…”